APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hyperimmune Globulins

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Selected research

Market Outlook & Growth Opportunities

Global Hyperimmune Globulins Market Outlook and Growth Opportunities 2026

26 December 2025194 pages

Choose your research edition.

Industry ResearchHyperimmune Globulins Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hyperimmune Globulins Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Hyperimmune Globulins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hyperimmune Globulins Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Hyperimmune Globulins Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

Global Hyperimmune Globulins key players include CSL Behring, Grifols, etc. Global top two manufacturers hold a share over 50%.

Read the full market overview

Asia-Pacific is the largest market, with a share about 30%, followed by Europe and North America, both have a share over 50 percent.

In terms of product, Rho(D) Immunoglobulins is the largest segment, with a share about 33%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

This report provides an overview of the global Hyperimmune Globulins market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hyperimmune Globulins and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hyperimmune Globulins sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hyperimmune Globulins market size, projected growth trends, production technologies, key applications, and end-use industries.

Hyperimmune Globulins Segment by Company

CSL Behring

Grifols

Biotest

Kedrion

CBPO

Emergent (Cangene)

Kamada

CNBG

Hualan Bio

Shanghai RAAS

Sichuan Yuanda Shuyang

ADMA Biologics

Hyperimmune Globulins Segment by Type

Hepatitis B Immunoglobulins

Rabies Immunoglobulins

Tetanus Immunoglobulins

Rho(D) Immunoglobulins

Other

Hyperimmune Globulins Segment by Application

Government Institutions

Private Sector

Other

Hyperimmune Globulins Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hyperimmune Globulins status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hyperimmune Globulins market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hyperimmune Globulins significant trends, drivers, influence factors in global and regions.

6. To analyze Hyperimmune Globulins competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hyperimmune Globulins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hyperimmune Globulins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hyperimmune Globulins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hyperimmune Globulins market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hyperimmune Globulins industry.

Chapter 3: Detailed analysis of Hyperimmune Globulins manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hyperimmune Globulins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hyperimmune Globulins in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hyperimmune Globulins Industry Trends Table 2. Hyperimmune Globulins Industry Drivers Table 3. Hyperimmune Globulins Industry Opportunities and Challenges Table 4. Hyperimmune Globulins Industry Restraints Table 5. Global Hyperimmune Globulins Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hyperimmune Globulins Revenue Share by Company (2021-2026) Table 7. Global Hyperimmune Globulins Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Hyperimmune Globulins Sales Volume Share by Company (2021-2026) Table 9. Global Hyperimmune Globulins Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Hyperimmune Globulins Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hyperimmune Globulins Key Company Manufacturing Base & Headquarters Table 12. Global Hyperimmune Globulins Company, Product Type & Application Table 13. Global Hyperimmune Globulins Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hyperimmune Globulins by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Hepatitis B Immunoglobulins Table 18. Significant Companies of Rabies Immunoglobulins Table 19. Significant Companies of Tetanus Immunoglobulins Table 20. Significant Companies of Rho(D) Immunoglobulins Table 21. Significant Companies of Other Table 22. Global Hyperimmune Globulins Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Hyperimmune Globulins Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Hyperimmune Globulins Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Hyperimmune Globulins Sales Volume Share by Type (2021-2026) Table 26. Global Hyperimmune Globulins Sales Volume Share by Type (2027-2032) Table 27. Global Hyperimmune Globulins Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hyperimmune Globulins Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Hyperimmune Globulins Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Hyperimmune Globulins Sales Value Share by Type (2021-2026) Table 31. Global Hyperimmune Globulins Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Government Institutions Table 33. Significant Companies of Private Sector Table 34. Significant Companies of Other Table 35. Global Hyperimmune Globulins Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Hyperimmune Globulins Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Hyperimmune Globulins Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Hyperimmune Globulins Sales Volume Share by Application (2021-2026) Table 39. Global Hyperimmune Globulins Sales Volume Share by Application (2027-2032) Table 40. Global Hyperimmune Globulins Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Hyperimmune Globulins Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Hyperimmune Globulins Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Hyperimmune Globulins Sales Value Share by Application (2021-2026) Table 44. Global Hyperimmune Globulins Sales Value Share by Application (2027-2032) Table 45. Global Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Hyperimmune Globulins Sales by Region (2021-2026) & (K Units) Table 47. Global Hyperimmune Globulins Sales Market Share by Region (2021-2026) Table 48. Global Hyperimmune Globulins Sales by Region (2027-2032) & (K Units) Table 49. Global Hyperimmune Globulins Sales Market Share by Region (2027-2032) Table 50. Global Hyperimmune Globulins Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Hyperimmune Globulins Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Hyperimmune Globulins Sales Value Share by Region (2021-2026) Table 53. Global Hyperimmune Globulins Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Hyperimmune Globulins Sales Value Share by Region (2027-2032) Table 55. Global Hyperimmune Globulins Market Average Price (USD/Unit) by Region (2021-2026) Table 56. Global Hyperimmune Globulins Market Average Price (USD/Unit) by Region (2027-2032) Table 57. Global Hyperimmune Globulins Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Hyperimmune Globulins Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Hyperimmune Globulins Sales by Country (2021-2026) & (K Units) Table 60. Global Hyperimmune Globulins Sales Market Share by Country (2021-2026) Table 61. Global Hyperimmune Globulins Sales by Country (2027-2032) & (K Units) Table 62. Global Hyperimmune Globulins Sales Market Share by Country (2027-2032) Table 63. Global Hyperimmune Globulins Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Hyperimmune Globulins Sales Value Market Share by Country (2021-2026) Table 65. Global Hyperimmune Globulins Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Hyperimmune Globulins Sales Value Market Share by Country (2027-2032) Table 67. CSL Behring Company Information Table 68. CSL Behring Business Overview Table 69. CSL Behring Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 70. CSL Behring Hyperimmune Globulins Product Portfolio Table 71. CSL Behring Recent Development Table 72. Grifols Company Information Table 73. Grifols Business Overview Table 74. Grifols Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 75. Grifols Hyperimmune Globulins Product Portfolio Table 76. Grifols Recent Development Table 77. Biotest Company Information Table 78. Biotest Business Overview Table 79. Biotest Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 80. Biotest Hyperimmune Globulins Product Portfolio Table 81. Biotest Recent Development Table 82. Kedrion Company Information Table 83. Kedrion Business Overview Table 84. Kedrion Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 85. Kedrion Hyperimmune Globulins Product Portfolio Table 86. Kedrion Recent Development Table 87. CBPO Company Information Table 88. CBPO Business Overview Table 89. CBPO Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. CBPO Hyperimmune Globulins Product Portfolio Table 91. CBPO Recent Development Table 92. Emergent (Cangene) Company Information Table 93. Emergent (Cangene) Business Overview Table 94. Emergent (Cangene) Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Emergent (Cangene) Hyperimmune Globulins Product Portfolio Table 96. Emergent (Cangene) Recent Development Table 97. Kamada Company Information Table 98. Kamada Business Overview Table 99. Kamada Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Kamada Hyperimmune Globulins Product Portfolio Table 101. Kamada Recent Development Table 102. CNBG Company Information Table 103. CNBG Business Overview Table 104. CNBG Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. CNBG Hyperimmune Globulins Product Portfolio Table 106. CNBG Recent Development Table 107. Hualan Bio Company Information Table 108. Hualan Bio Business Overview Table 109. Hualan Bio Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. Hualan Bio Hyperimmune Globulins Product Portfolio Table 111. Hualan Bio Recent Development Table 112. Shanghai RAAS Company Information Table 113. Shanghai RAAS Business Overview Table 114. Shanghai RAAS Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 115. Shanghai RAAS Hyperimmune Globulins Product Portfolio Table 116. Shanghai RAAS Recent Development Table 117. Sichuan Yuanda Shuyang Company Information Table 118. Sichuan Yuanda Shuyang Business Overview Table 119. Sichuan Yuanda Shuyang Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 120. Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio Table 121. Sichuan Yuanda Shuyang Recent Development Table 122. ADMA Biologics Company Information Table 123. ADMA Biologics Business Overview Table 124. ADMA Biologics Hyperimmune Globulins Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 125. ADMA Biologics Hyperimmune Globulins Product Portfolio Table 126. ADMA Biologics Recent Development Table 127. Key Raw Materials Table 128. Raw Materials Key Suppliers Table 129. Hyperimmune Globulins Distributors List Table 130. Hyperimmune Globulins Customers List Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Hyperimmune Globulins Product Image Figure 2. Global Hyperimmune Globulins Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hyperimmune Globulins Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hyperimmune Globulins Sales (2021-2032) & (K Units) Figure 5. Global Hyperimmune Globulins Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Hyperimmune Globulins Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Hepatitis B Immunoglobulins Image Figure 10. Rabies Immunoglobulins Image Figure 11. Tetanus Immunoglobulins Image Figure 12. Rho(D) Immunoglobulins Image Figure 13. Other Image Figure 14. Global Hyperimmune Globulins Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Hyperimmune Globulins Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Hyperimmune Globulins Sales Volume Share by Type (2021-2032) Figure 17. Global Hyperimmune Globulins Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hyperimmune Globulins Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Hyperimmune Globulins Sales Value Share by Type (2021-2032) Figure 20. Government Institutions Image Figure 21. Private Sector Image Figure 22. Other Image Figure 23. Global Hyperimmune Globulins Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Hyperimmune Globulins Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Hyperimmune Globulins Sales Volume Share by Application (2021-2032) Figure 26. Global Hyperimmune Globulins Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Hyperimmune Globulins Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Hyperimmune Globulins Sales Value Share by Application (2021-2032) Figure 29. Global Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Hyperimmune Globulins Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Hyperimmune Globulins Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Hyperimmune Globulins Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Hyperimmune Globulins Sales Value (2021-2032) & (US$ Million) Figure 34. North America Hyperimmune Globulins Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Hyperimmune Globulins Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Hyperimmune Globulins Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Hyperimmune Globulins Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Hyperimmune Globulins Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Hyperimmune Globulins Sales Value (2021-2032) & (US$ Million) Figure 40. South America Hyperimmune Globulins Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Hyperimmune Globulins Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Hyperimmune Globulins Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Hyperimmune Globulins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Hyperimmune Globulins Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Hyperimmune Globulins Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Hepatitis B Immunoglobulins
  • Rabies Immunoglobulins
  • Tetanus Immunoglobulins
  • Rho(D) Immunoglobulins
  • Other
Applications
  • Government Institutions
  • Private Sector
  • Other
Companies covered
  • CSL Behring
  • Grifols
  • Biotest
  • Kedrion
  • CBPO
  • Emergent (Cangene)
  • Kamada
  • CNBG
  • Hualan Bio
  • Shanghai RAAS
  • Sichuan Yuanda Shuyang
  • ADMA Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hyperimmune Globulins Sales Value (2021-2032)
  4. 1.2.2 Global Hyperimmune Globulins Sales Volume (2021-2032)
  5. 1.2.3 Global Hyperimmune Globulins Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hyperimmune Globulins Market Dynamics
  1. 2.1 Hyperimmune Globulins Industry Trends
  2. 2.2 Hyperimmune Globulins Industry Drivers
  3. 2.3 Hyperimmune Globulins Industry Opportunities and Challenges
  4. 2.4 Hyperimmune Globulins Industry Restraints
3 Hyperimmune Globulins Market by Company
  1. 3.1 Global Hyperimmune Globulins Company Revenue Ranking in 2025
  2. 3.2 Global Hyperimmune Globulins Revenue by Company (2021-2026)
  3. 3.3 Global Hyperimmune Globulins Sales Volume by Company (2021-2026)
  4. 3.4 Global Hyperimmune Globulins Average Price by Company (2021-2026)
  5. 3.5 Global Hyperimmune Globulins Company Ranking (2024-2026)
  6. 3.6 Global Hyperimmune Globulins Company Manufacturing Base and Headquarters
  7. 3.7 Global Hyperimmune Globulins Company Product Type and Application
  8. 3.8 Global Hyperimmune Globulins Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hyperimmune Globulins Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hyperimmune Globulins Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hyperimmune Globulins Market by Type
  1. 4.1 Hyperimmune Globulins Type Introduction
  2. 4.1.1 Hepatitis B Immunoglobulins
  3. 4.1.2 Rabies Immunoglobulins
  4. 4.1.3 Tetanus Immunoglobulins
  5. 4.1.4 Rho(D) Immunoglobulins
  6. 4.1.5 Other
  7. 4.2 Global Hyperimmune Globulins Sales Volume by Type
  8. 4.2.1 Global Hyperimmune Globulins Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hyperimmune Globulins Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Hyperimmune Globulins Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Hyperimmune Globulins Sales Value by Type
  12. 4.3.1 Global Hyperimmune Globulins Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Hyperimmune Globulins Sales Value by Type (2021-2032)
  14. 4.3.3 Global Hyperimmune Globulins Sales Value Share by Type (2021-2032)
5 Hyperimmune Globulins Market by Application
  1. 5.1 Hyperimmune Globulins Application Introduction
  2. 5.1.1 Government Institutions
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Hyperimmune Globulins Sales Volume by Application
  6. 5.2.1 Global Hyperimmune Globulins Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hyperimmune Globulins Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hyperimmune Globulins Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hyperimmune Globulins Sales Value by Application
  10. 5.3.1 Global Hyperimmune Globulins Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hyperimmune Globulins Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hyperimmune Globulins Sales Value Share by Application (2021-2032)
6 Hyperimmune Globulins Regional Sales and Value Analysis
  1. 6.1 Global Hyperimmune Globulins Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hyperimmune Globulins Sales by Region (2021-2032)
  3. 6.2.1 Global Hyperimmune Globulins Sales by Region: 2021-2026
  4. 6.2.2 Global Hyperimmune Globulins Sales by Region (2027-2032)
  5. 6.3 Global Hyperimmune Globulins Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hyperimmune Globulins Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hyperimmune Globulins Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hyperimmune Globulins Sales Value by Region (2027-2032)
  9. 6.5 Global Hyperimmune Globulins Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hyperimmune Globulins Sales Value (2021-2032)
  12. 6.6.2 North America Hyperimmune Globulins Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hyperimmune Globulins Sales Value (2021-2032)
  15. 6.7.2 Europe Hyperimmune Globulins Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hyperimmune Globulins Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hyperimmune Globulins Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hyperimmune Globulins Sales Value (2021-2032)
  21. 6.9.2 South America Hyperimmune Globulins Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hyperimmune Globulins Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hyperimmune Globulins Sales Value Share by Country, 2025 VS 2032
7 Hyperimmune Globulins Country-level Sales and Value Analysis
  1. 7.1 Global Hyperimmune Globulins Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hyperimmune Globulins Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hyperimmune Globulins Sales by Country (2021-2032)
  4. 7.3.1 Global Hyperimmune Globulins Sales by Country (2021-2026)
  5. 7.3.2 Global Hyperimmune Globulins Sales by Country (2027-2032)
  6. 7.4 Global Hyperimmune Globulins Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hyperimmune Globulins Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hyperimmune Globulins Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hyperimmune Globulins Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hyperimmune Globulins Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hyperimmune Globulins Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL Behring
  2. 8.1.1 CSL Behring Company Information
  3. 8.1.2 CSL Behring Business Overview
  4. 8.1.3 CSL Behring Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Behring Hyperimmune Globulins Product Portfolio
  6. 8.1.5 CSL Behring Recent Developments
  7. 8.2 Grifols
  8. 8.2.1 Grifols Company Information
  9. 8.2.2 Grifols Business Overview
  10. 8.2.3 Grifols Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Grifols Hyperimmune Globulins Product Portfolio
  12. 8.2.5 Grifols Recent Developments
  13. 8.3 Biotest
  14. 8.3.1 Biotest Company Information
  15. 8.3.2 Biotest Business Overview
  16. 8.3.3 Biotest Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Biotest Hyperimmune Globulins Product Portfolio
  18. 8.3.5 Biotest Recent Developments
  19. 8.4 Kedrion
  20. 8.4.1 Kedrion Company Information
  21. 8.4.2 Kedrion Business Overview
  22. 8.4.3 Kedrion Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Kedrion Hyperimmune Globulins Product Portfolio
  24. 8.4.5 Kedrion Recent Developments
  25. 8.5 CBPO
  26. 8.5.1 CBPO Company Information
  27. 8.5.2 CBPO Business Overview
  28. 8.5.3 CBPO Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CBPO Hyperimmune Globulins Product Portfolio
  30. 8.5.5 CBPO Recent Developments
  31. 8.6 Emergent (Cangene)
  32. 8.6.1 Emergent (Cangene) Company Information
  33. 8.6.2 Emergent (Cangene) Business Overview
  34. 8.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Emergent (Cangene) Hyperimmune Globulins Product Portfolio
  36. 8.6.5 Emergent (Cangene) Recent Developments
  37. 8.7 Kamada
  38. 8.7.1 Kamada Company Information
  39. 8.7.2 Kamada Business Overview
  40. 8.7.3 Kamada Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Kamada Hyperimmune Globulins Product Portfolio
  42. 8.7.5 Kamada Recent Developments
  43. 8.8 CNBG
  44. 8.8.1 CNBG Company Information
  45. 8.8.2 CNBG Business Overview
  46. 8.8.3 CNBG Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 CNBG Hyperimmune Globulins Product Portfolio
  48. 8.8.5 CNBG Recent Developments
  49. 8.9 Hualan Bio
  50. 8.9.1 Hualan Bio Company Information
  51. 8.9.2 Hualan Bio Business Overview
  52. 8.9.3 Hualan Bio Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Hualan Bio Hyperimmune Globulins Product Portfolio
  54. 8.9.5 Hualan Bio Recent Developments
  55. 8.10 Shanghai RAAS
  56. 8.10.1 Shanghai RAAS Company Information
  57. 8.10.2 Shanghai RAAS Business Overview
  58. 8.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai RAAS Hyperimmune Globulins Product Portfolio
  60. 8.10.5 Shanghai RAAS Recent Developments
  61. 8.11 Sichuan Yuanda Shuyang
  62. 8.11.1 Sichuan Yuanda Shuyang Company Information
  63. 8.11.2 Sichuan Yuanda Shuyang Business Overview
  64. 8.11.3 Sichuan Yuanda Shuyang Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Sichuan Yuanda Shuyang Hyperimmune Globulins Product Portfolio
  66. 8.11.5 Sichuan Yuanda Shuyang Recent Developments
  67. 8.12 ADMA Biologics
  68. 8.12.1 ADMA Biologics Company Information
  69. 8.12.2 ADMA Biologics Business Overview
  70. 8.12.3 ADMA Biologics Hyperimmune Globulins Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 ADMA Biologics Hyperimmune Globulins Product Portfolio
  72. 8.12.5 ADMA Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hyperimmune Globulins Value Chain Analysis
  2. 9.1.1 Hyperimmune Globulins Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hyperimmune Globulins Sales Mode & Process
  6. 9.2 Hyperimmune Globulins Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hyperimmune Globulins Distributors
  9. 9.2.3 Hyperimmune Globulins Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst